The Comprehensive Genetic Test for Familial Hyperlipidemia utilizes next-generation sequencing (NGS) to examine 4 genes associated with familial hypercholesterolemia and lipid metabolism disorders. It is a targeted gene panel specifically designed to support accurate diagnosis, risk assessment, and prevention.
More Information
The Comprehensive Genetic Test for Familial Hyperlipidemia is a targeted genetic test designed to evaluate hereditary causes of familial hypercholesterolemia, a metabolic disorder characterized by elevated blood cholesterol levels. The comprehensive genetic test for familial hyperlipidemia includes the analysis of 4 genes, along with selected non-coding variants, enabling a focused assessment of genetic factors associated with lipid metabolism disorders. It is particularly suitable for individuals with a clinical suspicion of familial hypercholesterolemia. This condition is characterized by impaired clearance of low-density lipoprotein (LDL) cholesterol, leading to its accumulation in the bloodstream and increased risk of early cardiovascular disease.
The comprehensive genetic test for familial hyperlipidemia includes key genes such as LDLR, APOB, PCSK9, and LDLRAP1, which are involved in cholesterol transport, receptor-mediated uptake, and regulation of lipid metabolism. LDLR encodes the LDL receptor responsible for removing LDL cholesterol from circulation, while APOB is essential for LDL particle structure and receptor binding. PCSK9 regulates the degradation of LDL receptors, and LDLRAP1 is involved in receptor internalization. Disruptions in these pathways result in elevated circulating cholesterol levels. The comprehensive genetic test for familial hyperlipidemia is indicated in individuals presenting with clinical or biochemical features suggestive of familial hypercholesterolemia.
The clinical spectrum of familial hypercholesterolemia includes markedly elevated cholesterol levels, premature coronary artery disease, and increased risk of myocardial infarction at a young age. Physical findings may include tendon xanthomas, particularly affecting the Achilles tendon and tendons of the hands, as well as xanthelasmata around the eyelids. Cholesterol deposition in the cornea may lead to the appearance of arcus cornealis. Disease severity varies depending on the genetic background, with untreated individuals exhibiting significantly increased cardiovascular risk. The condition is often underdiagnosed, despite its relatively high prevalence in the general population.
The purpose of the comprehensive genetic test for familial hyperlipidemia is to identify pathogenic variants associated with familial hypercholesterolemia, supporting accurate diagnosis and differentiation from other causes of hyperlipidemia. Genetic findings contribute to improved understanding of lipid metabolism disorders and support appropriate disease classification. The identification of specific genetic alterations assists in risk assessment, prognosis evaluation, and the development of appropriate long-term monitoring strategies.
A higher genetic risk is confirmed when pathogenic mutations are found in genes associated with familial hypercholesterolemia, including LDLR, APOB, and PCSK9. A lower risk may be inferred when no mutations are detected, though comprehensive clinical follow-up is still essential. The integration of genetic data with clinical findings and biochemical lipid profile is critical for precise diagnosis, prognosis, and long-term patient care.
The test is performed in a clinical laboratory accredited to ISO 15189 and certified by CLIA and CAP, ensuring the validity, accuracy and international recognition of the results.
